Interview: Roberto Bellini, President & CEO, Bellus Health, Canada
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s…
Bellus Health
Last updated: 13.02.2014
Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.
Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
275 Armand-Frappier Blvd.
Laval,
Quebec
Canada
H7V 4A7
Tel.: (450) 680-4500
Fax: (450) 680-4501
Interviews
Related
Canada / Concrete Steps Toward National Pharmacare
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific…
Canada / Federal Consultations on a National Strategy for Rare Disease Drugs
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
Canada / The Evolution of Medical Cannabis Legislation
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
Canada / Has the Time Truly Come for Trudeau’s ‘National Pharmacare’?
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
Canada / Pharma News Roundup September 2020
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
Pricing / Drugmakers Push Back Against Canada's New Regulations
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory…
Alzheimer's / Canadian-Led Innovation Post-Aducanumab
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
Canada / Global Pharma has Reinvented R&D: Will Canadian Start-Ups Lead the Next Phase?
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Opinion / A New Approach to Rare Diseases in Canada
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to…
Pharma Faces / Marina Vasiliou, Biogen Canada
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…
Canada / Collective Impact in the Health Charity Sector
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to…
Patents: A Key Factor in Winning the Cannabis Arms Race
A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial…
